Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 48

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 48
---
     | Reported revenue                                                                                                                                                                 |
| Adjusted Free Cash Flow       |     | 20%       |     | Cash flows from operating activities minus capital expenditures, excluding litigation expenses and one-time events such as restructuring and acquisitions, and similar items.    |
| Strategic Business Objectives |     | 20%       |     | Nine key business objectives related to the successful launches of new products in targeted timeframes in 2024.  If achieved, each SBO counted as one point on the payout scale. |

The compensation committee set our revenue metric with (i) a minimum achievement of $650M, (ii) a target achievement of $725M and (iii) a maximum achievement of $775M. The adjusted free cash flow metric had (i) a minimum achievement of ($30M), (ii) a target achievement of $9M and (iii) a maximum achievement of $30M. The strategic business objectives metric had (i) a minimum achievement of at least four objectives achieved, (ii) a target achievement of at least seven objectives achieved and (iii) a maximum achievement of all nine of the objectives. Any metric that is below the minimum achievement would result in no funding for the applicable metric. Achievement of the applicable performance metric at the minimum level would result in 25% funding, target would result in 100% funding and the maximum would result in 175% funding (except for the strategic business objectives which would have a maximum funding of 150%). In the event that one of our performance metrics were between the levels discussed above, the resulting funding would be determined using linear interpolation between points.

At the end of fiscal year 2024, revenue reached $611M, adjusted free cash flow totaled $41M, and six out of nine strategic business objectives (SBOs) were met, resulting in a 50% bonus pool funding for executive officers, as shown in the table below. The compensation committee then evaluated individual performance for each NEO, excluding the CEO, based on both qualitative and quantitative factors related to their respective roles. After this assessment, the committee determined that all executive officers would receive the same 50% payout (except for Mr. McAnear who separated from the company effective August 30, 2024, thus did not earn any bonus payment for 2024).

#### 10X GENOMICS, INC.472025 PROXY STATEMENT
| Metric                        |     | FYE’24 Result       |     | Metric Result |     | Weighting |